Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2021 Mar 3:2021.02.26.21252554.
doi: 10.1101/2021.02.26.21252554.

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil

Nuno R Faria  1   2   3 Thomas A Mellan  1 Charles Whittaker  1 Ingra M Claro  2   4 Darlan da S Candido  2   3 Swapnil Mishra  1 Myuki A E Crispim  5   6 Flavia C Sales  2   4 Iwona Hawryluk  1 John T McCrone  7 Ruben J G Hulswit  8 Lucas A M Franco  2   4 Mariana S Ramundo  2   4 Jaqueline G de Jesus  2   4 Pamela S Andrade  2   4 Thais M Coletti  2   4 Giulia M Ferreira  9 Camila A M Silva  2   4 Erika R Manuli  2   4 Rafael H M Pereira  10 Pedro S Peixoto  11 Moritz U Kraemer  3 Nelson Gaburo Jr  12 Cecilia da C Camilo  13 Henrique Hoeltgebaum  14 William M Souza  15 Esmenia C Rocha  2   4 Leandro M de Souza  2   4 Mariana C de Pinho  2   4 Leonardo J T Araujo  16 Frederico S V Malta  17 Aline B de Lima  17 Joice do P Silva  17 Danielle A G Zauli  17 Alessandro C de S Ferreira  17 Ricardo P Schnekenberg  18 Daniel J Laydon  1 Patrick G T Walker  1 Hannah M Schlüter  14 Ana L P Dos Santos  13 Maria S Vidal  13 Valentina S Del Caro  13 Rosinaldo M F Filho  13 Helem M Dos Santos  13 Renato S Aguiar  19 José L P Modena  20 Bruce Nelson  21 James A Hay  22   23 Melodie Monod  14 Xenia Miscouridou  14 Helen Coupland  1 Raphael Sonabend  1 Michaela Vollmer  1 Axel Gandy  14 Marc A Suchard  24 Thomas A Bowden  8 Sergei L K Pond  25 Chieh-Hsi Wu  26 Oliver Ratmann  14 Neil M Ferguson  1 Christopher Dye  3 Nick J Loman  27 Philippe Lemey  28 Andrew Rambaut  7 Nelson A Fraiji  5   29 Maria do P S S Carvalho  5   30 Oliver G Pybus  3   31 Seth Flaxman  1 Samir Bhatt  1   32 Ester C Sabino  2   4
Affiliations

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil

Nuno R Faria et al. medRxiv. .

Update in

  • Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.
    Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, Crispim MAE, Sales FCS, Hawryluk I, McCrone JT, Hulswit RJG, Franco LAM, Ramundo MS, de Jesus JG, Andrade PS, Coletti TM, Ferreira GM, Silva CAM, Manuli ER, Pereira RHM, Peixoto PS, Kraemer MUG, Gaburo N Jr, Camilo CDC, Hoeltgebaum H, Souza WM, Rocha EC, de Souza LM, de Pinho MC, Araujo LJT, Malta FSV, de Lima AB, Silva JDP, Zauli DAG, Ferreira ACS, Schnekenberg RP, Laydon DJ, Walker PGT, Schlüter HM, Dos Santos ALP, Vidal MS, Del Caro VS, Filho RMF, Dos Santos HM, Aguiar RS, Proença-Modena JL, Nelson B, Hay JA, Monod M, Miscouridou X, Coupland H, Sonabend R, Vollmer M, Gandy A, Prete CA Jr, Nascimento VH, Suchard MA, Bowden TA, Pond SLK, Wu CH, Ratmann O, Ferguson NM, Dye C, Loman NJ, Lemey P, Rambaut A, Fraiji NA, Carvalho MDPSS, Pybus OG, Flaxman S, Bhatt S, Sabino EC. Faria NR, et al. Science. 2021 May 21;372(6544):815-821. doi: 10.1126/science.abh2644. Epub 2021 Apr 14. Science. 2021. PMID: 33853970 Free PMC article.

Abstract

Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite high levels of previous infection there. Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor. Molecular clock analysis shows that P.1 emergence occurred around early November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.4-2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Authors declare that they have no competing interests.

Figures

Fig. 1.
Fig. 1.. SARS-CoV-2 epidemiological, diagnostic, genomic and mobility data from Manaus.
(A) Dark solid line shows the 7-day rolling average of the COVID-19 confirmed and suspected daily time series of hospitalisations in Manaus. Admissions in Manaus are from Fundação de Vigilância em Saúde do Amazonas (75). Green dots represent daily severe acute respiratory mortality records from the SIVEP-Gripe (Sistema de Informação de Vigilância Epidemiológica da Gripe) database (71). SARI = severe acute respiratory infections. Excess burial records based on data from Manaus Mayor’s office are shown in red dots for comparison (see Materials and Methods). The arrow denotes 6 December 2020, the date of the first P.1 case identified in Manaus by our study. (B) Maximum likelihood tree (n=974) with B.1.1.28, P.1 and P.2 sequences, with collapsed views of P.1 and P.2 clusters and highlighting other sequences from Manaus, Brazil). Ancestral branches leading to P.1 and P.2 are shown as dashed lines. See fig. S3 for a more detail phylogeny. Scale bar is shown in units of nucleotide substitutions per site (s/s). (C) Number of air travel passengers from Manaus to all states in Brazil was obtained from National Civil Aviation Agency of Brazil (www.gov.br/anac). The ISO 3166–2:BR codes of the states with genomic reports of P.1 (GISAID (76), as of 24 Feb 2021), are shown in bold. An updated list of GISAID genomes and reports of P.1 worldwide is available at https://covlineages.org/global_report_P.1.html. (D) Number of genome sequences from Manaus belonging to lineages of interest (see Materials and Methods); spike mutations of interest are denoted.
Fig. 2.
Fig. 2.. Visualization of the time-calibrated maximum clade credibility tree reconstruction for B.1.1.28, P.1 and P.2 lineages (n=974) in Brazil.
Terminal branches and tips of Amazonas state are coloured in brown and those from other locations are coloured in green. Nodes with posterior probabilities of <0.5 have been collapsed into polytomies and their range of divergence dates are illustrated as shaded expanses.
Fig. 3.
Fig. 3.. Temporal variation in the proportion of sequenced genomes belonging to P.1, and trends in RT-qPCR Ct values for COVID-19 infections in Manaus.
(A) Logistic function fitting to the proportion of genomes in sequenced infections that have been classified as P.1 (black circles, size indicating number of infections sequenced), divided up into time-periods where the predicted proportion of infections that are due to P.1 is <1/3 (light brown), between 1/3 and 2/3 (green) and greater than 2/3 (grey). For the model fit, darker ribbon represents the 50% credible interval, and lighter ribbon represents the 95% credible interval. For the data points, grey thick line is the 50% exact Binomial confidence interval and the thinner line is the 95% exact Binomial confidence interval. (B) Ct values for genes E and N in a sample of symptomatic cases presenting for testing at a healthcare facility in Manaus, stratified according to the period defined in (A) in which the oropharyngeal and nasal swab collections occurred in. (C) Ct values for genes E and N in a subsample of 184 infections included in (B) that had their genomes sequenced (dataset A).
Fig. 4.
Fig. 4.. Estimates of P.1’s epidemiological characteristics inferred from a multicategory Bayesian transmission model fitted to data from Manaus, Brazil
(A) Joint posterior distribution of the cross-immunity and transmissibility increase inferred through fitting the model to mortality and genomic data. Grey contours refer to posterior density intervals ranging from the 95% and 50% isoclines. Marginal posterior distributions for each parameter shown along each axis. (B) As for (A) but showing the joint-posterior distribution of cross-immunity and the inferred relative risk of morality in the period following P.1’s emergence compared to the period prior. (C) Daily incidence of COVID-19 mortality. Points show severe acute respiratory mortality records from the SIVEP-Gripe database (71), brown and green ribbons show model fit for COVID-19 mortality incidence, disaggregated by mortality attributable to non-P.1 lineages (brown) and the P.1 lineage (green). (D) Estimate of the proportion of P.1 infections through time in Manaus. Black data points with error bars are the empirical proportion observed in genomically sequenced cases (see Fig. 3A) and green ribbons (dark = 50% BCI, light = 95% BCI) the model fit to the data. (E) Estimated cumulative infection incidence for the P.1 and non-P.1 categories. Black data points with error bars are reversion-corrected estimates of seroprevalence from blood donors in Manaus (2), coloured ribbons are the model predictions of cumulative infection incidence for non-P.1 lineages (brown) and P.1 lineages (green). These points are shown for reference only and were not used to fit the model. (F) Bayesian posterior estimates of trends in reproduction number Rt for the P.1 and non-P.1 categories.

References

    1. Hallal P. C. et al. , SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. The Lancet Global Health 8, e1390–e1398 (2020). - PMC - PubMed
    1. Buss L. F. et al. , Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 371, 288–292 (2021). - PMC - PubMed
    1. Álvarez-Antonio C M.-S. G., Calampa C, Casanova W, Carey C, Alava F, Rodríguez-Ferrucci H, Quispe AM, Seroprevalence of Anti-SARS-CoV-2 Antibodies in Iquitos, Loreto, Peru. medRxiv, (2021). - PMC - PubMed
    1. Mercado M., Ospina M., Institutoo Nacional de Salud, “Seroprevalencia de SARS-CoV-2 durante la epidemia en Colombia: estudio país” (https://www.ins.gov.co/BibliotecaDigital/Seroprevalencia-estudio-colombi..., 2020).
    1. Portal da Fundação de Vigilância em Saúde do Amazonas, “Perfil clínico e demográfico dos casos de Covid-19 no estado do Amazonas: uma análise comparativa entre 2020 e 2021,” No. 17 (2021)

Publication types

LinkOut - more resources